The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform
Ailsa Hart - One of the best experts on this subject based on the ideXlab platform.
-
review article faecal transplantation therapy for Gastrointestinal Disease
Alimentary Pharmacology & Therapeutics, 2011Co-Authors: J Landy, Hafid O Alhassi, Simon D Mclaughlin, A Walker, Paul J Ciclitira, R J Nicholls, S K Clark, Ailsa HartAbstract:BACKGROUND: Evidence is emerging regarding the relationship between a dysbiosis of the human gut microbiota and a number of Gastrointestinal Diseases as well as Diseases beyond the gut. Probiotics have been investigated in many Gastrointestinal Disease states, with variable and often modest outcomes. Faecal transplantation is an alternative approach to manipulate the gut microbiota. AIM: To review the use of faecal transplantation therapy for the management of Gastrointestinal disorders. METHODS: Available articles on faecal transplantation in the management of Gastrointestinal disorders were identified using a Pubmed search and bibliographies of review articles on the subject were collated. RESULTS: A total of 239 patients who had undergone faecal transplantation were reported. Seventeen of 22 studies of faecal transplantation were in fulminant or refractory Clostridium difficile. Studies of faecal transplantation are heterogeneous regarding the patients, donors, screening, methods of administration and definition of response. Faecal transplantation for C. difficile has been demonstrated to be effective in 145/166 (87%) patients. Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel Disease. CONCLUSIONS: Faecal transplantation has been reported with good outcomes for fulminant and refractory C. difficile. No adverse effects of faecal transplantation have been reported. However, there are no level 1 data of faecal transplantation and reports to date may suffer from reporting bias of positive outcomes and under-reporting of adverse effects. This therapy holds great promise, where a dysbiosis of the gut microbiota is responsible for Disease and further studies are necessary to explore this potential.
J Landy - One of the best experts on this subject based on the ideXlab platform.
-
review article faecal transplantation therapy for Gastrointestinal Disease
Alimentary Pharmacology & Therapeutics, 2011Co-Authors: J Landy, Hafid O Alhassi, Simon D Mclaughlin, A Walker, Paul J Ciclitira, R J Nicholls, S K Clark, Ailsa HartAbstract:BACKGROUND: Evidence is emerging regarding the relationship between a dysbiosis of the human gut microbiota and a number of Gastrointestinal Diseases as well as Diseases beyond the gut. Probiotics have been investigated in many Gastrointestinal Disease states, with variable and often modest outcomes. Faecal transplantation is an alternative approach to manipulate the gut microbiota. AIM: To review the use of faecal transplantation therapy for the management of Gastrointestinal disorders. METHODS: Available articles on faecal transplantation in the management of Gastrointestinal disorders were identified using a Pubmed search and bibliographies of review articles on the subject were collated. RESULTS: A total of 239 patients who had undergone faecal transplantation were reported. Seventeen of 22 studies of faecal transplantation were in fulminant or refractory Clostridium difficile. Studies of faecal transplantation are heterogeneous regarding the patients, donors, screening, methods of administration and definition of response. Faecal transplantation for C. difficile has been demonstrated to be effective in 145/166 (87%) patients. Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel Disease. CONCLUSIONS: Faecal transplantation has been reported with good outcomes for fulminant and refractory C. difficile. No adverse effects of faecal transplantation have been reported. However, there are no level 1 data of faecal transplantation and reports to date may suffer from reporting bias of positive outcomes and under-reporting of adverse effects. This therapy holds great promise, where a dysbiosis of the gut microbiota is responsible for Disease and further studies are necessary to explore this potential.
Sharon L Deem - One of the best experts on this subject based on the ideXlab platform.
-
MORTALITY OF CAPTIVE BLACK-FOOTED FERRETS (MUSTELA NIGRIPES) AT SMITHSONIAN'S NATIONAL ZOOLOGICAL PARK, 1989–2004
Journal of Zoo and Wildlife Medicine, 2007Co-Authors: Ellen Bronson, R. Mitchell Bush, Samantha M. Wisely, Suzan Murray, Tabitha Viner, Sharon L DeemAbstract:Abstract Black-footed ferret (Mustela nigripes) mortality was investigated retrospectively based on the pathology records of 107 captive animals held at Smithsonian's National Zoological Park from 1989 to 2004. The majority of deaths in neonates were due to cannibalism (n = 42; 64.6%) and maternal trauma (n = 11; 16.9%); both of these causes of mortality decreased during the study period. Prior to 2001, juvenile mortality was most often caused by Gastrointestinal Disease (n = 11; 52.4%), including coccidiosis, salmonellosis, and clostridium infection. In 2001, improvements in husbandry, hygiene, and medical treatment led to decreases in juvenile mortality associated with Gastrointestinal Disease. The most common causes of death in adult ferrets were renal or neoplastic Disease. The etiology of the high prevalence of renal Disease in the last 4 yr of the study is unknown; it was not associated with increasing age or inbreeding. Improved hygiene and vigilant monitoring for signs of Gastrointestinal and rena...
-
mortality of captive black footed ferrets mustela nigripes at smithsonian s national zoological park 1989 2004
Journal of Zoo and Wildlife Medicine, 2007Co-Authors: Ellen Bronson, Mitchell R Bush, Samantha M. Wisely, Suzan Murray, Tabitha Viner, Sharon L DeemAbstract:Abstract Black-footed ferret (Mustela nigripes) mortality was investigated retrospectively based on the pathology records of 107 captive animals held at Smithsonian's National Zoological Park from 1989 to 2004. The majority of deaths in neonates were due to cannibalism (n = 42; 64.6%) and maternal trauma (n = 11; 16.9%); both of these causes of mortality decreased during the study period. Prior to 2001, juvenile mortality was most often caused by Gastrointestinal Disease (n = 11; 52.4%), including coccidiosis, salmonellosis, and clostridium infection. In 2001, improvements in husbandry, hygiene, and medical treatment led to decreases in juvenile mortality associated with Gastrointestinal Disease. The most common causes of death in adult ferrets were renal or neoplastic Disease. The etiology of the high prevalence of renal Disease in the last 4 yr of the study is unknown; it was not associated with increasing age or inbreeding. Improved hygiene and vigilant monitoring for signs of Gastrointestinal and rena...
Lloyd Mayer - One of the best experts on this subject based on the ideXlab platform.
-
pathogenesis and treatment of Gastrointestinal Disease in antibody deficiency syndromes
The Journal of Allergy and Clinical Immunology, 2009Co-Authors: Shradha Agarwal, Lloyd MayerAbstract:Primary humoral immune deficiencies are characterized by limited antibody responses secondary to either impaired B-lymphocyte development or B-cell responses to T-lymphocyte signals. Given that the Gastrointestinal tract is the largest lymphoid organ in the body, it is not surprising that intestinal Diseases are common in immunodeficiency. These Gastrointestinal Diseases can be classified into one of 4 groups, infection, malignancy, inflammatory, and autoimmune, and can mimic other known Disease processes, such as inflammatory bowel Disease and celiac sprue. The exact pathogenesis of these Gastrointestinal disorders in the setting of systemic immunodeficiency is still under investigation. However, studies suggest that defects in antibody deficiency alone do not result in Gastrointestinal Disease but rather that defects in cellular immunity are also involved. Treatment is difficult given an already immunocompromised state, and often therapy with immunomodulators is required for more severe processes.
S K Clark - One of the best experts on this subject based on the ideXlab platform.
-
review article faecal transplantation therapy for Gastrointestinal Disease
Alimentary Pharmacology & Therapeutics, 2011Co-Authors: J Landy, Hafid O Alhassi, Simon D Mclaughlin, A Walker, Paul J Ciclitira, R J Nicholls, S K Clark, Ailsa HartAbstract:BACKGROUND: Evidence is emerging regarding the relationship between a dysbiosis of the human gut microbiota and a number of Gastrointestinal Diseases as well as Diseases beyond the gut. Probiotics have been investigated in many Gastrointestinal Disease states, with variable and often modest outcomes. Faecal transplantation is an alternative approach to manipulate the gut microbiota. AIM: To review the use of faecal transplantation therapy for the management of Gastrointestinal disorders. METHODS: Available articles on faecal transplantation in the management of Gastrointestinal disorders were identified using a Pubmed search and bibliographies of review articles on the subject were collated. RESULTS: A total of 239 patients who had undergone faecal transplantation were reported. Seventeen of 22 studies of faecal transplantation were in fulminant or refractory Clostridium difficile. Studies of faecal transplantation are heterogeneous regarding the patients, donors, screening, methods of administration and definition of response. Faecal transplantation for C. difficile has been demonstrated to be effective in 145/166 (87%) patients. Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel Disease. CONCLUSIONS: Faecal transplantation has been reported with good outcomes for fulminant and refractory C. difficile. No adverse effects of faecal transplantation have been reported. However, there are no level 1 data of faecal transplantation and reports to date may suffer from reporting bias of positive outcomes and under-reporting of adverse effects. This therapy holds great promise, where a dysbiosis of the gut microbiota is responsible for Disease and further studies are necessary to explore this potential.
